Intraperitoneal prophylaxis with CpG oligodeoxynucleotides protects neutropenic mice against intracerebral Escherichia coli K1 infection

Journal of Neuroinflammation

Volumn 11, Issue , 2014, Pages

  Ribes, Sandra ^a   Meister, Tanja ^a   Ott, Martina ^a   Redlich, Sandra ^a   Janova, Hana ^a   Hanisch, Uwe Karsten ^a   Nessler, Stefan ^a   Nau, Roland ^a,b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b Sleep Laboratory   (Germany)

Author keywords

CNS infection; CpG ODN; Escherichia coli; IFN ; IL 12 IL 23p40; MIP 1 ; Neutropenia

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; INTERLEUKIN 12P40; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TOLL LIKE RECEPTOR 9;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; CYTOKINE PRODUCTION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; IMMUNOCOMPETENCE; INFECTION PREVENTION; MENINGOENCEPHALITIS; MOUSE; NEUROPROTECTION; NEUTROPENIA; NONHUMAN; PROTEIN BLOOD LEVEL; SURVIVAL RATE; TISSUE LEVEL; TREATMENT OUTCOME;

ANIMALS; ANTIGENS, CD; CENTRAL NERVOUS SYSTEM; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FLOW CYTOMETRY; GUANIDINE; MENINGOENCEPHALITIS; MICE; MICE, KNOCKOUT; OLIGODEOXYRIBONUCLEOTIDES; SPLEEN; TOLL-LIKE RECEPTOR 9;

EID: 84892729272     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-11-14     Document Type: Article

References (45)

1. Ram S, Lewis LA, Rice PA. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev 2010, 23:740-780. 10.1128/CMR.00048-09, 2952982, 20930072.
2. Sakran W, Levin C, Kenes Y, Colodner R, Koren A. Clinical spectrum of serious bacterial infections among splenectomized patients with hemoglobinopathies in Israel: a 37-year follow-up study. Infection 2012, 40:35-39. 10.1007/s15010-011-0178-5, 21866338.
3. Escudier E, Cordonnier C, Poirier J. Infections of the central nervous system in malignant hemopathies. Rev Neurol (Paris) 1986, 142:116-125.
4. Kim KS. Strategy of Escherichia coli for crossing the blood-brain barrier. J Infect Dis 2002, 186:S220-S224. 10.1086/344284, 12424701.
5. Lu CH, Chang WN, Chuang YC, Chang HW. Gram-negative bacillary meningitis in adult post-neurosurgical patients. Surg Neurol 1999, 52:438-443. 10.1016/S0090-3019(99)00129-9, 10595761.
6. Yang TM, Lu CH, Huang CR, Tsai HH, Tsai NW, Lee PY, Chien CC, Chang WN. Clinical characteristics of adult Escherichia coli meningitis. Jpn J Infect Dis 2005, 58:168-170.
7. Liu WM, van der Zeijst BA, Boog CJ, Soethout EC. Aging and impaired immunity to influenza viruses: implications for vaccine development. Hum Vaccin 2011, 7:94-98. 10.4161/hv.7.0.14568, 21301210.
8. Klinman DM, Yi AK, Beaucage SL, Conover JS, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A 1996, 93:2879-2883. 10.1073/pnas.93.7.2879, 39727, 8610135.
9. Weiner GJ. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J Leukoc Biol 2000, 68:455-463.
10. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745. 10.1038/35047123, 11130078.
11. Ribes S, Ebert S, Czesnik D, Regen T, Zeug A, Bukowski S, Mildner A, Eiffert H, Hanisch UK, Hammerschmidt S, Nau R. Toll-like receptor prestimulation increases phagocytosis of Escherichia coli DH5alpha and Escherichia coli K1 strains by murine microglial cells. Infect Immun 2009, 77:557-564. 10.1128/IAI.00903-08, 2612236, 18981243.
12. Ribes S, Ebert S, Regen T, Agarwal A, Tauber SC, Czesnik D, Spreer A, Bunkowski S, Eiffert H, Hanisch UK, Hammerschmidt S, Nau R. Toll-like receptor stimulation enhances phagocytosis and intracellular killing of nonencapsulated and encapsulated Streptococcus pneumoniae by murine microglia. Infect Immun 2010, 78:865-871. 10.1128/IAI.01110-09, 2812218, 19933834.
13. Barrier M, Lacroix-Lamandé S, Mancassola R, Auray G, Bernardet N, Chaussé AM, Uematsu S, Akira S, Laurent F. Oral and intraperitoneal administation of phosphorothioate oligodeoxynucleotides leads to control of Cryptosporidium parvum infection in neonatal mice. J Infect Dis 2006, 193:1400-1407. 10.1086/503748, 16619188.
14. Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS, Klinman DM. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol 1999, 162:2291-2298.
15. Gramzinski RA, Doolan DL, Sedegah M, Davis HL, Krieg AM, Hoffman SL. Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect Immun 2001, 69:1643-1649. 10.1128/IAI.69.3.1643-1649.2001, 98068, 11179339.
16. Hickey AJ, Lin JS, Kummer LW, Szaba FM, Duso DK, Tighe M, Parent MA, Smiley ST. Intranasal prophylaxis with CpG oligodeoxynucleotide can protect against Yersinia pestis infection. Infect Immun 2013, 81:2123-2132. 10.1128/IAI.00316-13, 3676034, 23545300.
17. Krieg AM, Love HL, Yi AK, Harty JT. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol 1998, 161:2428-2434.
18. Miyagi K, Kawakami K, Kinjo Y, Uezu K, Kinjo T, Nakamura K, Saito A. CpG oligodeoxynucleotides promote the host protective response against infection with Cryptococcus neoformans through induction of interferon-gamma production by CD4+ T cells. Clin Exp Immunol 2005, 140:220-229. 10.1111/j.1365-2249.2005.02772.x, 1809361, 15807845.
19. Weighardt H, Feterowski C, Veit M, Rump M, Wagner H, Holzmann B. Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. J Immunol 2000, 165:4537-4543.
20. Wongratanacheewin S, Kespichayawattana W, Intachote P, Pichyangkul S, Sermswan RW, Krieg AM, Sirisinha S. Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei. Infect Immun 2004, 72:4494-4502. 10.1128/IAI.72.8.4494-4502.2004, 470634, 15271908.
21. Gerber J, Raivich G, Wellmer A, Noeske C, Kunst T, Werner A, Brück W, Nau R. A mouse model of Streptococcus pneumoniae meningitis mimicking several features of human disease. Acta Neuropathol 2001, 101:499-508.
22. Ribes S, Regen T, Meister T, Tauber SC, Schütze S, Mildner A, Mack M, Hanisch UK, Nau R. Resistance of the brain to Escherichia coli K1 Infection depends on MyD88 signaling and the contribution of neutrophils and monocytes. Infect Immun 2013, 81:1810-1819. 10.1128/IAI.01349-12, 3648016, 23478323.
23. Hu W, Nessler S, Hemmer B, Eagar TN, Kane LP, Leliveld SR, Müller-Schiffmann A, Gocke AR, Lovett-Racke A, Ben LH, Hussain RZ, Breil A, Elliott JL, Puttaparthi K, Cravens PD, Singh MP, Petsch B, Stitz L, Racke MK, Korth C, Stüve O. Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling. Brain 2010, 133:375-388. 10.1093/brain/awp298, 2822628, 20145049.
24. Scheffel J, Regen T, Van Rossum D, Seifert S, Ribes S, Nau R, Parsa R, Harris RA, Boddeke HW, Chuang HN, Pukrop T, Wessels JT, Jürgens T, Merkler D, Brück W, Schnaars M, Simons M, Kettenmann H, Hanisch UK. Toll-like receptor activation reveals developmental reorganization and unmasks responder subsets of microglia. Glia 2012, 60:1930-1943. 10.1002/glia.22409, 22911652.
25. McCusker RH, Kelley KW. Immune-neural connections: how the immune system's response to infectious agents influences behavior. J Exp Biol 2013, 216:84-98. 10.1242/jeb.073411, 3515033, 23225871.
26. Raghavan S, Nyström J, Fredriksson M, Holmgren J, Harandi AM. Orally administered CpG oligodeoxynucleotide induces production of CXC and CC chemokines in the gastric mucosa and suppresses bacterial colonization in a mouse model of Helicobacter pylori infection. Infect Immun 2003, 71:7014-7022. 10.1128/IAI.71.12.7014-7022.2003, 308895, 14638791.
27. Tasaka S, Kamata H, Miyamoto K, Nakano Y, Shinoda H, Kimizuka Y, Fujiwara H, Hasegawa N, Fujishima S, Miyasho T, Ishizaka A. Intratracheal synthetic CpG oligodeoxynucleotide causes acute lung injury with systemic inflammatory response. Respir Res 2009, 10:84. 10.1186/1465-9921-10-84, 2761862, 19772669.
28. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003, 19:641-644. 10.1016/S1074-7613(03)00296-6, 14614851.
29. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Vaisberg E, Churakova T, Liu M, Gorman D, Wagner J, Zurawski S, Liu Y, Abrams JS, Moore KW, Rennick D, de Waal-Malefyt R, Hannum C, Bazan JF, Kastelein RA. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13:715-720. 10.1016/S1074-7613(00)00070-4, 11114383.
30. Chace JH, Hooker NA, Mildenstein KL, Krieg AM, Cowdery JS. Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol 1997, 84:185-193. 10.1006/clin.1997.4380, 9245551.
31. Benson A, Murray S, Divakar P, Burnaevskiy N, Pifer R, Forman J, Yarovinsky F. Microbial infection-induced expansion of effector T cells overcomes the suppressive effects of regulatory T cells via an IL-2 deprivation mechanism. J Immunol 2012, 188:800-810. 10.4049/jimmunol.1100769, 3253229, 22147768.
32. Wang YY, He XY, Cai YY, Wang ZJ, Lu SH. The variation of CD4+CD25+ regulatory T cells in the periphery blood and tumor microenvironment of non-small cell lung cancer patients and the downregulation effects induced by CpG ODN. Target Oncol 2011, 6:147-154. 10.1007/s11523-011-0182-9, 21611754.
33. Spanaus KS, Nadal D, Pfister HW, Seebach J, Widmer U, Frei K, Gloor S, Fontana A. C-X-C and C-C chemokines are expressed in the cerebrospinal fluid in bacterial meningitis and mediate chemotactic activity on peripheral blood-derived polymorphonuclear and mononuclear cells in vitro. J Immunol 1997, 158:1956-1964.
34. Galanakis E, Di Cello F, Paul-Satyaseela M, Kim KS. Escherichia coli K1 induces IL-8 expression in human brain microvascular endothelial cells. Eur Cytokine Netw 2006, 17:260-265.
35. Chui R, Dorovini-Zis K. Regulation of CCL2 and CCL3 expression in human brain endothelial cells by cytokines and lipopolysaccharide. J Neuroinflammation 2010, 7:1. 10.1186/1742-2094-7-1, 2819252, 20047691.
36. Carpentier A, Laigle-Donadey F, Zohar S, Capelle L, Behin A, Tibi A, Martin-Duverneuil N, Sanson M, Lacomblez L, Taillibert S, Puybasset L, Van Effenterre R, Delattre JY, Carpentier AF. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol 2006, 8:60-66. 10.1215/S1522851705000475, 1871923, 16443949.
37. Carpentier A, Metellus P, Ursu R, Zohar S, Lafitte F, Barrié M, Meng Y, Richard M, Parizot C, Laigle-Donadey F, Gorochov G, Psimaras D, Sanson M, Tibi A, Chinot O, Carpentier AF. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol 2010, 12:401-408. 10.1093/neuonc/nop047, 2940609, 20308317.
38. Kozak W, Wrotek S, Kozak A. Pyrogenicity of CpG-DNA in mice: role of interleukin-6, cyclooxygenases, and nuclear factor-kappaB. Am J Physiol Regul Integr Comp Physiol 2006, 290:R871-R880.
39. Iliev AI, Stringaris AK, Nau R, Neumann H. Neuronal injury mediated via stimulation of microglial Toll-like receptor 9 (TLR9). FASEB J 2004, 18:412-414.
40. Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, Luong R, Rosenblum MD, Steinman L, Levitsky HI, Tse V, Levy R. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 2013, 123:2447-2463. 10.1172/JCI64859, 3668834, 23728179.
41. Dalpke A, Zimmermann S, Heeg K. CpG DNA in the prevention and treatment of infections. BioDrugs 2002, 16:419-431. 10.2165/00063030-200216060-00003, 12463765.
42. Klinman DM, Yamshchikov G, Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 1997, 158:3635-3639.
43. Sato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen MD, Silverman GJ, Lotz M, Carson DA, Raz E. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996, 273:352-354. 10.1126/science.273.5273.352, 8662521.
44. Bot A, Bona C. Genetic immunization of neonates. Microbes Infect 2002, 4:511-520. 10.1016/S1286-4579(02)01566-6, 11932202.
45. Søgaard OS, Lohse N, Harboe ZB, Offersen R, Bukh AR, Davis HL, Schønheyder HC, Østergaard L. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin Infect Dis 2010, 51:42-50. 10.1086/653112, 20504165.